Metagenomi Therapeutics Market Cap 2022-2025 | MGX

Metagenomi Therapeutics market cap history and chart from 2022 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Metagenomi Therapeutics market cap as of February 05, 2026 is $0.05B.
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.054B $0.052B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $40.098B 12.44
BridgeBio Pharma (BBIO) United States $14.490B 0.00
Dr Reddy's Laboratories (RDY) India $11.689B 18.18
Supernus Pharmaceuticals (SUPN) United States $2.814B 23.04
Bausch Health Cos (BHC) Canada $2.099B 1.49
Amphastar Pharmaceuticals (AMPH) United States $1.315B 9.47
Taysha Gene Therapies (TSHA) United States $1.244B 0.00
Personalis (PSNL) United States $0.738B 0.00
Assembly Biosciences (ASMB) United States $0.428B 0.00
Sol-Gel Technologies (SLGL) Israel $0.184B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00